Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2 FY27 revenue grew 33% y-y to INR418 Cr; EBITDA doubled to INR77 Cr (+118% y-y); PAT INR28.5 Cr vs loss last year - Base business revenue up 37% y-y to INR327 Cr; EBITDA margin expanded 440 bps to 23.6% - Ibuprofen revenue grew 21% y-y; EBITDA loss narrowed to near breakeven - Filed 2 DMFs in FY27 so far; targeting 5 total this year - Net debt reduced to ~INR500 Cr; net debt/EBITDA improved to 1.8x from 3.2x - Gross margin for base business ~50% impacted by raw material costs; Ibuprofen gross margin recovered to 36% - Strategic review of Ibuprofen business ongoing; decision expected in 12 weeks - Management focused on operational excellence, capacity debottlenecking, and cash generation